After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

“Emphysema is part of a group of lung conditions which comes under the umbrella term chronic obstructive pulmonary disease ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Study finds home high-flow therapy may enhance COPD recovery after severe exacerbations, improving symptoms and reducing ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.